title: Breast Cancer: State of the Art and New Findings.
abstract: Advances in research have a highly influential role to play in the strategy of early detection, treatment and aftercare of breast cancer and therefore everyday clinical practice. Newly-defined prognosis factors and a new form of molecular subtype classification, for example, are intended to help identify patients who will actually benefit from chemotherapy. In the field of neoadjuvant chemotherapy, the inclusion of the angiogenesis inhibitor Bevacizumab and dual antiHER2 therapy is being discussed. What's more, where defined criteria are met, even with positive sentinel lymph nodes, axillary dissection is not performed; besides bisphosphonates RANKL antibody Denosumab is now an option in the treatment of bone metastases.
authors.affiliation: Women's Clinic, Hospital of the Heinrich Heine University of Düsseldorf, Düsseldorf.
authors.forename: C
authors.initials: C
authors.lastname: Melcher
authors.affiliation: Women's Clinic, Hospital of the Heinrich Heine University of Düsseldorf, Düsseldorf.
authors.forename: C
authors.initials: C
authors.lastname: Scholz
authors.affiliation: Department and Outpatient Clinic for Gynaecology and Obstetrics - Innenstadt, Hospital of the Ludwig Maximilian , University of Munich, Munich.
authors.forename: B
authors.initials: B
authors.lastname: Jäger
authors.affiliation: Women's Clinic, Hospital of the Heinrich Heine University of Düsseldorf, Düsseldorf.
authors.forename: C
authors.initials: C
authors.lastname: Hagenbeck
authors.affiliation: Department and Outpatient Clinic for Gynaecology and Obstetrics - Innenstadt, Hospital of the Ludwig Maximilian , University of Munich, Munich.
authors.forename: B
authors.initials: B
authors.lastname: Rack
authors.affiliation: Women's Clinic, Hospital of the Heinrich Heine University of Düsseldorf, Düsseldorf.
authors.forename: W
authors.initials: W
authors.lastname: Janni
keywords: breast cancer; chemotherapy; endocrine therapy; molecular genetic subtypes; prognosis; radiotherapy; targeted therapy